openPR Logo
Press release

Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth

03-13-2019 05:34 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Coherent Market Insights

Peyronie’s Disease Treatment

Peyronie’s Disease Treatment

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/61

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/61

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/61

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/61

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth here

News-ID: 1649903 • Views:

More Releases from Coherent Market Insights

Green Packaging Market: Industry Size, Share, Growth, and Forecast 2024-2031 | Amcor Limited, Bemis Company Inc., Sealed Air Corporation
Green Packaging Market: Industry Size, Share, Growth, and Forecast 2024-2031 | A …
Global Green Packaging Market was valued at US$ 2,08,000 Mn in 2024 in terms of revenue, exhibiting a CAGR of 4.97% during the forecast period (2024 to 2031). The Green Packaging Market from 2024 to 2031 refers to the global industry segment focused on packaging solutions that prioritize environmental sustainability throughout their lifecycle, from sourcing materials to end-of-life disposal. This period is characterized by rapid growth driven by increasing consumer and
Algae Market: Business Growth, Development Factors, Current and Future Trends By 2024-2031 | Cyanotech Corporation, Dic Corporation
Algae Market: Business Growth, Development Factors, Current and Future Trends By …
Global algae market was valued at US$ 4,681.4 Million in 2024 and is expected to reach at 7,927.1 Million during the forecast period (2024 to 2031), exhibiting a CAGR of 6.81 %. The Algae Market from 2024 to 2031 refers to the global industry segment focused on the cultivation, harvesting, and utilization of various types of algae for commercial purposes. This period is characterized by significant growth driven by increasing
Fabric Wash And Care Product Market: Industry Size, Emerging Trends, Key Players, Forecast Until 2031 | Unilever, Henkel AG & Co.KGaA, Procter and Gamble
Fabric Wash And Care Product Market: Industry Size, Emerging Trends, Key Players …
The Fabric Wash and Care Product Market from 2024 to 2031 encompasses the global industry segment focused on products designed for cleaning, maintaining, and enhancing the longevity of textiles and fabrics. This period is characterized by steady growth driven by increasing consumer awareness of hygiene, sustainability, and textile durability. Key trends include advancements in formulation technologies to address specific fabric types, stains, and environmental concerns, such as biodegradability and eco-friendly
Offshore Drilling Rigs Market Report: Industry Size, Share, Trends, Analysis, and Forecast By 2024-2031 | Transocean, Ensco, Seadrill, COSL, Diamond Offshore
Offshore Drilling Rigs Market Report: Industry Size, Share, Trends, Analysis, an …
The Offshore Drilling Rigs Market from 2024 to 2031 refers to the global industry segment focused on the exploration and extraction of oil and gas reserves located beneath the seabed using specialized drilling rigs. This period is characterized by dynamic growth driven by increasing offshore exploration activities, technological advancements in drilling equipment, and rising global energy demand. Key trends include innovations in rig designs, automation, and safety technologies aimed at

All 5 Releases


More Releases for Peyronie

Peyronie Disease Treatment Market is Set to See Revolutionary Growth in Decade C …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The Global Peyronie Disease Treatment Report offers a thorough overview of the market, including data on market size, share, and forecasts for the future. The total breakdown of data by manufacturers, regions, types, and applications, as well as market drivers, opportunities, and disadvantages, are shown in this report. The Global Peyronie Disease Treatment Market Report will examine the effects of COVID-19 on the sector. The Global Peyronie Disease
Peyronie’s Disease Treatment Market 2019 | Explore Future Growth by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market it is Creating Real Change in the Healthca …
Peyronie's disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
With Xiaflex the only FDA approved product for this disease, Endo dominates the …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product